Latest Commentary

Indivior CEO looks beyond 2015 after troubled Reckitt pharma unit's spinoff

It's new year, new company for Reckitt Benckiser's pharma unit, spun off into Indivior last week. And while 2015 might not be the easiest for the newly minted drugmaker, CEO Shaun Thaxter says investors have much to look forward to a little further down the line.

Get out your binoculars for FiercePharma's traditional holiday trend-spotting

As surely as Linus and Lucy's jazz theme plays in shops decorated with Santa's and garland, and blue-and-white-wrapped chocolates and menorah candles appear on store shelves; as surely as calendar pages flutter into the trash, FiercePharma peers into the murky future to predict which headlines we'll be writing next year.

Pfizer believes a dose of confidence will help it sell biosimilars

As drug prices climb and expensive newcomers inspire payers to get creative to contain costs, a window is widening for meds that can drive efficiency for healthcare systems and address consumers' needs. That's where biosimilars come in--or so Pfizer figures.

We publish, you pick: FiercePharma's 10 best-read stories of 2014

In pharma, here are the top 10 news stories of the year so far, based on web traffic.

Who are the stars of personalized meds? Roche, Novartis and J&J

Targeted drugs, personalized medicine, stratified therapy--whatever you call it, using biomarkers to identify particular patients for particular drugs has been hailed as a boon for patients and a savvy strategy for pharma.

Takeda scrambles to fix glitches in Contrave direct-delivery launch

Takeda Pharmaceuticals saw a problem with recent obesity drug launches: Cost. Private insurers and public payers were refusing coverage--or foisting big copays onto patients--dragging down new drugs marketed by Vivus and Eisai.

Sanofi's U.S. sales team gets its close-up--and a promised makeover

Sanofi's U.S. diabetes sales team is under a worldwide spotlight--and not because it's time to take a bow.

Diabetes pricing war? Sanofi, Lilly and Novo each have their ideas

When Sanofi announced that its franchise would suffer next year because of U.S. payer contracts, the natural follow-up question was this: Does this mean a diabetes pricing war? If Sanofi had to boost its rebates to win coverage--which the company admits it did--then that means its rivals, including Eli Lilly and Novo Nordisk, have, too.

Cancer survivor's petition pleads with Roche for lower Kadcyla price

Drugmakers are accustomed to grappling with government payers and PBMs over prices. But a pricing fight directly with patients? That's not your everyday occurrence.

Merck hops onto HBCU network to step up its brand in the African-American community

Merck's marketing team is adding another arrow to its quiver of community-oriented campaigns: a partnership with HBCU Connect, a niche media network targeting alumni and students of historically black colleges and universities.